Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
Guardant Health, Inc. (Nasdaq: GH), announced that its market leading liquid biopsy, Guardant360®, will be a covered benefit for the members of the health plans associated with eviCore, a technology assessment company. The test will be considered medically necessary to assist in selecting therapy for patients with advanced lung cancer. When the eviCore policy becomes effective July 1, Guardant360 will have added coverage for over 38 million lives in 2019, including with Health Care Service Corporation in Illinois, Montana, New Mexico, Oklahoma, and Texas, Independence Blue Cross, Highmark Blue Cross Blue Shield, Blue Cross Blue Shield of Tennessee, and Government Employees Health Association/Federal Employees Program. This will increase total lung cancer coverage for Guardant360 to more than 150 million Americans, including for all Medicare beneficiaries, members of Cigna, Blue Shield of California, UPMC Health Plan, BCBS FEP (Federal Employees Program), and many others.
Since its introduction in 2014, Guardant360 has been ordered by more than 6,000 oncologists for more than 80,000 patients with advanced cancer to help select treatment. The best-in-class performance of the assay is evidenced by more than 100 peer-reviewed publications, which address its analytical validity, clinical validity, and clinical utility in multiple tumor types.
The coverage decision by eviCore follows the publication of a recent prospective study supporting the use of Guardant360 to guide the first-line treatment of patients with advanced lung cancer. In an independent review of Guardant360 published in JAMA Oncology, researchers at the University of Pennsylvania found that Guardant360 has sensitivity and detection rates comparable to tissue testing, and that patients responded to the treatment selected based on Guardant360 testing.